Nj\u00eb tjet\u00ebr alarm i r\u00ebnd\u00eb po ngrihet mbi m\u00ebnyr\u00ebn se si Agjencia Komb\u00ebtare e Barnave dhe Pajisjeve Mjek\u00ebsore, n\u00ebn ndikimin e drejtp\u00ebrdrejt\u00eb t\u00eb Klodian Allajbeut dhe Rasim Hamzaraj po ushtron p\u00ebrgjegj\u00ebsin\u00eb e saj ndaj sh\u00ebndetit publik.<\/p>\n\n\n\n
N\u00eb qend\u00ebr t\u00eb shqet\u00ebsimit ndodhet nj\u00eb medikament antitumoral i prodhuar n\u00eb Malt\u00eb me p\u00ebrfaq\u00ebsues vendas, shp\u00ebrndar\u00ebsin farmaceutik Megapharma, i cili, sipas burimeve t\u00eb besueshme, nuk ka p\u00ebrmbushur kriteret laboratorike gjat\u00eb analizave fillestare, por megjithat\u00eb ka avancuar n\u00eb procesin e regjistrimit.<\/p>\n\n\n\n
Sipas t\u00eb nj\u00ebjtave burimeve, mostrat e para t\u00eb dor\u00ebzuara p\u00ebr analiz\u00eb kan\u00eb rezultuar problematike, nd\u00ebrsa m\u00eb pas jan\u00eb z\u00ebvend\u00ebsuar me mostra t\u00eb tjera, t\u00eb cilat kan\u00eb mund\u00ebsuar vijimin e procedur\u00ebs. Nj\u00eb praktik\u00eb e till\u00eb, p\u00ebrb\u00ebn nj\u00eb shkelje t\u00eb r\u00ebnd\u00eb t\u00eb parimeve t\u00eb siguris\u00eb farmaceutike dhe nj\u00eb rrezik t\u00eb drejtp\u00ebrdrejt\u00eb p\u00ebr pacient\u00ebt onkologjik\u00eb.<\/p>\n\n\n\n
Pyetjet q\u00eb lindin k\u00ebrkojn\u00eb p\u00ebrgjigje se pse u pranuan mostra t\u00eb reja pas d\u00ebshtimit t\u00eb analizave fillestare si dhe kush e mori k\u00ebt\u00eb vendim. Nd\u00ebrsa shqet\u00ebsim \u00ebsht\u00eb n\u00ebse agjencia e barnave po funksionon si garant i siguris\u00eb, apo si nj\u00eb hallk\u00eb formale q\u00eb mbyll syt\u00eb.<\/p>\n\n\n\n
Agjensia e barnave ka detyrimin ligjor dhe moral t\u00eb sqaroj\u00eb publikisht n\u00ebse procedurat e ndjekura, rezultatet reale t\u00eb analizave laboratorike, dhe arsyet pse nj\u00eb produkt i kontestuar ka kaluar filtrat zyrtar\u00eb. Sh\u00ebndeti i pacient\u00ebve nuk \u00ebsht\u00eb statistik\u00eb dhe nuk mund t\u00eb trajtohet si formalitet administrativ.<\/p>\n\n\n\n
Top Channel ka k\u00ebrkuar nga agjencia komb\u00ebtare e barnave informacion p\u00ebr k\u00ebt\u00eb rast duke e pyetur se sa aplikime p\u00ebr tu pajisur me autorizim p\u00ebr tregtim ka patur p\u00ebrgjat\u00eb vitit 2025 p\u00ebr medikamentin Nilotinib dhe datat p\u00ebrkat\u00ebse? Cil\u00ebt jan\u00eb operator\u00ebt? A jan\u00eb analizuar k\u00ebto barna gjat\u00eb procedur\u00ebs s\u00eb autorizimit p\u00ebr tregtim? \u00c7far\u00eb rezultatesh ka patur gjat\u00eb analizimit? N\u00ebse medikamenti ka shfaqur probleme gjat\u00eb analiz\u00ebs, \u00e7far\u00eb masash jan\u00eb marr\u00eb kundrejt operator\u00ebve q\u00eb kan\u00eb aplikuar? A jan\u00eb refuzuar k\u00ebto praktika? N\u00eb rast se jo t\u00eb gjitha praktikat jan\u00eb refuzuar, cilat jan\u00eb arsyet p\u00ebr k\u00ebt\u00eb trajtim t\u00eb diferencuar t\u00eb aplikimeve dhe p\u00ebr rrjedhoj\u00eb edhe t\u00eb operator\u00ebve? A \u00ebsht\u00eb vijuar m\u00eb tej p\u00ebr pajisjen me autorizim p\u00ebr tregtim t\u00eb k\u00ebtyre medikamenteve? N\u00ebse po, cil\u00ebt jan\u00eb operator\u00ebt t\u00eb cilat kan\u00eb marr\u00eb autorizimin p\u00ebr tregtim?<\/p>\n\n\n\n
Ky skandal \u00ebsht\u00eb nj\u00eb material I mjaftuesh\u00ebm q\u00eb SPAK t\u00eb investigoj\u00eb e t\u00eb zbardhe \u00e7far\u00eb po ndodh p\u00ebr t\u00eb mbrojtur interesat e pacient\u00ebve nd\u00ebrsa aktualisht duket se jan\u00eb l\u00ebn\u00eb n\u00eb dor\u00eb t\u00eb uris\u00eb p\u00ebr p\u00ebrfitime financiare t\u00eb Klodian Allajbeut, Rasim Hamzaraj dhe Petrit Vasilit.<\/p>","protected":false},"excerpt":{"rendered":"
Nj\u00eb tjet\u00ebr alarm i r\u00ebnd\u00eb po ngrihet mbi m\u00ebnyr\u00ebn se si Agjencia Komb\u00ebtare e Barnave dhe Pajisjeve Mjek\u00ebsore, n\u00ebn ndikimin e drejtp\u00ebrdrejt\u00eb t\u00eb Klodian Allajbeut dhe Rasim Hamzaraj po ushtron p\u00ebrgjegj\u00ebsin\u00eb e saj ndaj sh\u00ebndetit publik. N\u00eb qend\u00ebr t\u00eb shqet\u00ebsimit ndodhet nj\u00eb medikament antitumoral i prodhuar n\u00eb Malt\u00eb me p\u00ebrfaq\u00ebsues vendas, shp\u00ebrndar\u00ebsin farmaceutik Megapharma, i […]<\/p>\n","protected":false},"author":2037,"featured_media":426431,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241,5380,231,235],"tags":[],"class_list":{"0":"post-426430","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-aktualitet","8":"category-kryesore","9":"category-lajme","10":"category-vendi"},"_links":{"self":[{"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/posts\/426430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/users\/2037"}],"replies":[{"embeddable":true,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/comments?post=426430"}],"version-history":[{"count":1,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/posts\/426430\/revisions"}],"predecessor-version":[{"id":426432,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/posts\/426430\/revisions\/426432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/media\/426431"}],"wp:attachment":[{"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/media?parent=426430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/categories?post=426430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zjarr.tv\/en\/wp-json\/wp\/v2\/tags?post=426430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}